Navigation Links
Boehringer Ingelheim and Lilly's new oral type 2 diabetes treatment for adults, Jentadueto™ (linagliptin/metformin hydrochloride) tablets, now available in U.S. pharmacies
Date:3/7/2012

RIDGEFIELD, Conn. and INDIANAPOLIS, March 7, 2012 /PRNewswire/ --

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced Jentadueto™ (linagliptin/metformin hydrochloride) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S.

JENTADUETO is a new prescription medication for patients who need to control their blood sugar.  Taken twice daily, it combines two diabetes medicines – the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin and metformin – in one tablet. Linagliptin is marketed in the U.S. as Tradjenta™ 5mg once-daily tablets. JENTADUETO was approved by the U.S. Food and Drug Administration (FDA) on January 30, 2012, as a prescription medicine used along with diet and exercise to improve glycemic control in adults with type 2 diabetes when treatment with both linagliptin and metformin is appropriate. JENTADUETO is not for the treatment of type 1 diabetes or diabetic ketoacidosis (increased ketones in the blood or urine) and it has not been studied in combination with insulin. The product label contains a boxed warning for the risk of lactic acidosis, a serious metabolic complication that can occur due to metformin accumulation during treatment with JENTADUETO.

"By combining two important diabetes medicines in a single tablet, JENTADUETO provides people with type 2 diabetes another option to control their blood sugar," said David Pass, PharmD, vice president, cardiovascular and metabolic disorders marketing, Boehringer Ingelheim Pharmaceuticals, Inc. "Making JENTADUETO available quickly following its approval further demonstrates Boehringer Ingelheim and Lilly's shared commitment to address the needs of the millions of Americans living with type 2 diabetes."

JENTADUETO provides physicians with options to adjust th
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
4. Boehringer Ingelheim Unveils Diabetes Pipeline
5. Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer
6. Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
7. New Boehringer Ingelheim Science Quest Mobile Laboratory Brings Hands-On Science Education to Priority Connecticut Elementary Schools
8. Boehringer Ingelheim Affirms Safety of Telmisartan With an Analysis of 50,000 Patients and Strongly Disagrees With the Publication of Sipahi et al in Lancet Oncology June 2010
9. -- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes
10. Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
11. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)...  The Mesothelioma Victims Center is incredibly passionate ... the best possible compensation, and they are also extremely ... cancer caused by exposure to asbestos or their ... treatment options such as a recent possible medical breakthrough. ... Center anytime at 866-714-6466. http://MesotheliomaVictimsCenter.Com ...
(Date:5/22/2015)... , May 22, 2015   InspireMD, Inc. ... stent embolic protection systems ("EPS"), today announced that its CGuard ... lead by principle investigator Prof. Piotr Musialek , at ... Paris, France . PARADIGM, an ... R cutaneous c A roti D revascularization I ...
(Date:5/22/2015)...  In a sweeping analysis assessing the current state ... researchers conclude that there remains considerable room for ... age groups, but especially for adolescents and young adults. ... treatment, underscoring the need to address barriers to care ... type 1 patients achieve optimal metabolic control. ...
Breaking Medicine Technology:Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 5InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5
... SAN DIEGO, Feb. 17, 2011 Orexigen® Therapeutics, Inc. (Nasdaq: ... Graham Cooper, senior vice president, Finance, CFO and treasurer. Mr. ... has decided to leave the Company for personal reasons.  He ... accepting the CFO role in 2006.  Mr. Cooper will remain ...
... Feb. 17, 2011 In celebration of the 31st Annual ... NXTM ), a leading manufacturer of innovative dialysis products, today ... System One for home hemodialysis.  The System One is the ... the FDA. "This new milestone demonstrates growing ...
Cached Medicine Technology:Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer 2Orexigen® Therapeutics, Inc. Announces Upcoming Departure of Chief Financial Officer 3In Celebration of the 31st Annual Dialysis Conference, NxStage® Announces Over 5,000 Patients Using the System One™ for Home Hemodialysis 2In Celebration of the 31st Annual Dialysis Conference, NxStage® Announces Over 5,000 Patients Using the System One™ for Home Hemodialysis 3
(Date:5/24/2015)... New York, New York (PRWEB) May 24, 2015 ... of testosterone treatment lawsuits ( http://www.testosteronelawsuithub.com/ ) has ... discuss the progress of the multidistrict litigation. According ... Court, Northern District of Illinois, the Conference will ... p.m. (In re: Testosterone Replacement Therapy Product Liability ...
(Date:5/24/2015)... Medicx Media Solutions http://www.medicxmedia.com ... Jay Krihak as its head of programmatic strategy ... its expertise and leadership position in the data ... sectors. , Krihak is an experienced, award-winning agency ... led sales planning teams for mobile platform Jumptap. ...
(Date:5/23/2015)... 2015 On Saturday, May 23, 2015, over ... for Branches Florida City exactly five years to the day ... 2010. , A large fire tore through the Branches United ... 2010 in the middle of the night as neighbors, staff ... declared arson even though it is suspected that the fire ...
(Date:5/23/2015)... San Diego, CA (PRWEB) May 23, 2015 ... businesses, especially small businesses, are finding it increasingly difficult ... Those businesses which fail to provide adequate insurance for ... healthcare for businesses been such an integral part of ... provide more affordable healthcare for businesses, Online USA Doctors ...
(Date:5/23/2015)... 23, 2015 Manufacturers are now required to ... (HSPF) of 8.2. Experts in the field agree that the ... , The HSPF score is what miles per gallon is ... the unit. Although the minimum HSPF score has been raised ... an HSPF score north of 12. Indeed, the regulation was ...
Breaking Medicine News(10 mins):Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 3Health News:Medicx Media Solutions Expands Executive Team 2Health News:Five Years After Fire, Branches Rebuilds Playground 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:Parker & Sons Welcomes the Department of Energy’s Water Heater Regulation 2
... Oct. 11 SeaView IPA, an Oxnard, CA ... P. Bangasser Memorial,Award for Quality Improvement from the ... a special Awards Ceremony at the 6th,Annual Pay-for-Performance ... The IHA is a statewide leadership group ...
... 2007 Physicians at UT Southwestern Medical Center are the first ... radioactive pellet, or seed, is implanted into a mass or suspicious ... removal. , During the procedure, a radiologist uses a needle to ... of rice, into the mass. Once lodged, surgeons use a wand ...
... to Support Amendment to Hologic,s 1999 Equity ... ... Inc.,(Nasdaq: HOLX ), a leading provider of state-of-the-art diagnostic and,digital ... independent proxy advisory service, recommends that,Hologic stockholders vote "FOR" the Company,s ...
... Brochure Outlines Step-by-Step Process and Provides Sample Appeal,Letter, ... many seniors peace of mind that they will have,access ... individual,plan rules, the medicine that,s prescribed by the doctor ... but they need,to know what they can do about ...
... MEMPHIS, Tenn., Oct. 11 Baptist Memorial Health ... the University of Memphis,today, bringing its recent total ... million. Last month, Baptist contributed $1 million ... to Southwest Tennessee Community,College,s nursing, natural sciences and ...
... allows hospital pharmacies to accurately manage costs and ... ... 11 Omnicell, Inc.,(Nasdaq: OMCL ) a leading provider of ... efficiency, today,announced the Omnicell WorkflowRx 5.0 central pharmacy automation solution.,With its ...
Cached Medicine News:Health News:MED3OOO Client Wins IHA Pay-for-Performance Award 2Health News:MED3OOO Client Wins IHA Pay-for-Performance Award 3Health News:New 'seed' therapy helps pinpoint breast tumors with more accuracy 2Health News:ISS Recommends Hologic Stockholders Vote 'FOR' Merger With Cytyc 2Health News:ISS Recommends Hologic Stockholders Vote 'FOR' Merger With Cytyc 3Health News:ISS Recommends Hologic Stockholders Vote 'FOR' Merger With Cytyc 4Health News:New Resource Explains What Seniors Can Do if Medicare Denies Coverage of Their Medicines 2Health News:Baptist Memorial Health Care Donates More Than $3 Million to Tennessee Universities and Colleges 2Health News:Omnicell Introduces the Next Generation Central Pharmacy Automation Solution 2Health News:Omnicell Introduces the Next Generation Central Pharmacy Automation Solution 3
For the qualitative detection of human Chorionic Gonadotrophin (HCG) in urine or urine and serum specimens...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: